FRAMINGHAM, Mass., March 19, 2013 /PRNewswire/ -- Boston Heart Diagnostics, a pioneer in personalized diagnostics and care plans for patients with or at risk for heart disease, has received $450,000 in tax incentives through the Life Sciences Tax Incentive Program, pledging to create 35 new Massachusetts jobs in 2013. Boston Heart was one of just 25 companies to receive the tax incentive through the program, which is jointly administered by the Massachusetts Life Sciences Center and the Massachusetts Department of Revenue. Last year, the company received a $220,000 tax incentive through the program, pledging to create 31 Massachusetts full-time-equivalent (FTE) jobs in 2012; in fact the company added 55.
"Boston Heart is the embodiment of what the Life Sciences Tax Incentive Program was designed to achieve, and we are very honored to have received this award, which will help us to continue to realize our ambitious growth goals," commented Boston Heart President and CEO Susan Hertzberg . "This past fall, we were honored to be named one of the top places to work in Massachusetts by the Boston Globe, and a 'Rising Star' winner for the Team Massachusetts Economic Impact Awards, which celebrates companies that have made outstanding contributions to the Massachusetts economy. We are extremely proud of these accomplishments, however, we are prouder still of the important difference we make every day in helping to improve the lives of patients – through our unique panels of diagnostic tests and patient wellness services. We are combining the very latest in diagnostics with a consumer-oriented mindset to create tools, including a patient portal and other mobile touch-points, that drive patient engagement in his or her own heart health and motivate the patient to comply with lifestyle changes that can reduce cardiovascular risk dramatically."
About Boston Heart Diagnostics (BostonHeartDiagnostics.com)
Boston Heart Diagnostics focuses solely on cardiovascular disease – the number one cause of death in the United States. We offer clients an unparalleled combination of proprietary tests, actionable information, and dedicated service and support – partnering with healthcare providers so they can provide the best CVD patient care possible. There's much more to cardiovascular disease than "good" (HDL) and "bad" (LDL) cholesterol. Studies show that traditional statin drug therapy to lower LDL-C reduces the relative risk of heart attack by only 25%. Boston Heart, established in 2007, targets the 75% relative risk for a cardiovascular event that remains AFTER lowering LDL cholesterol. Our proprietary algorithm analyzes test results in light of relevant patient history and the latest peer-reviewed scientific data to produce personalized reports and plans that include specific therapeutic and lifestyle strategies tailored for each individual patient. When it comes to CVD management, Boston Heart Diagnostics is leading the charge to turn the promise of personalized medicine into a reality.
Media contact: Caroline Grossman -- 781.771.5579 -- email@example.com
|SOURCE Boston Heart Diagnostics|
Copyright©2012 PR Newswire.
All rights reserved